Ivermecatin induces cytotoxic effects in SUP-B15 cell line
Authors:
- Olga Rasiyanti SiregarOSOlga Rasiyanti Siregar
- Arlinda Sari WahyuniAWArlinda Sari Wahyuni
- Ayodhia Pitaloka PasaribuAPAyodhia Pitaloka Pasaribu
- Deri EdiantoDEDeri Edianto
- I Dewa Gede UgrasenaIUI Dewa Gede Ugrasena
- Rina AmeliaRARina Amelia
- Inke Nadia Diniyanti LubisILInke Nadia Diniyanti Lubis
- Muhammad RusdaMRMuhammad Rusda
Open Access
- 1 September 2025
- journal article
- Published by Hacettepe University Institute of Child Health in The Turkish Journal of Pediatrics
- Vol. 67 (4) , 569-574
Abstract
Background. Glucocorticoids remain the primary treatment for acute lymphoblastic leukemia (ALL) in children. However, glucocorticoid-resistant ALL exhibits increased mortality rates. To overcome resistance and improve management strategies, alternative therapeutic agents are required. Ivermectin (IVM), widely used as an anthelmintic agent, has been reported to possess anticancer properties through various mechanisms. These properties suggest IVM as a potential alternative treatment for ALL. This study aims to evaluate the role of IVM in inducing cytotoxic effects in the ALL cell line SUP-B15. Methods. The ALL cell line SUP-B15 was examined following treatment with IVM at concentrations of 5, 10, and 20 μM. The 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay was used to assess cytotoxic effects of IVM, including measurements of optical density, cell inhibition, and cell viability. Results. IVM demonstrated inhibitory effects on SUP-B15 cells starting at a low dose of 5 μM. The half maximal inhibitory concentration (IC50) of IVM was 5 µM, showing an inhibitory effect of 54.18 ± 0.03% (95% confidence interval: 54.11-54.25%; p < 0.001). Treatment with 10 μM IVM demonstrated the most significant inhibitory effect (59.05 ± 0.1%) and the lowest cell viability (40.95 ± 0.01%). Conclusions. IVM holds potential as a promising alternative therapeutic agent for the treatment of ALL.Keywords
This publication has 21 references indexed in Scilit:
- Glucocorticoid Therapy in Acute Lymphoblastic Leukemia: Navigating Short-Term and Long-Term Effects and Optimal Regimen SelectionCurrent Hematologic Malignancy Reports, 2024
- Dasatinib overcomes glucocorticoid resistance in B-cell acute lymphoblastic leukemiaNature Communications, 2023
- Chemotherapy induces plasmatic antioxidant changes in pediatric patients with acute lymphoid leukemia B that correlate to disease prognosisCurrent Research in Immunology, 2022
- BAX and SMAC regulate bistable properties of the apoptotic caspase systemScientific Reports, 2021
- Importin β1 regulates cell growth and survival during adult T cell leukemia/lymphoma therapyInvestigational New Drugs, 2020
- Repurposing anthelmintic agents to eradicate resistant leukemiaBlood Cancer Journal, 2020
- Pharmacokinetics of ascending doses of ivermectin in Trichuris trichiura-infected children aged 2–12 yearsJournal of Antimicrobial Chemotherapy, 2019
- An overview of apoptosis assays detecting DNA fragmentationMolecular Biology Reports, 2018
- Antibiotic ivermectin selectively induces apoptosis in chronic myeloid leukemia through inducing mitochondrial dysfunction and oxidative stressBiochemical and Biophysical Research Communications, 2018
- Epidemiological patterns of leukaemia in 184 countries: a population-based studyThe Lancet Haematology, 2018